home.aspx
   
. home.aspx home.aspx

ARCHIVED NEWS


    PFIZERS KEYS TO JUGGLING 8 U.S. LAUNCHES? ORGANIZATION, ACCOUNTABILITY, CLEAR GOALS

    Jul 19, 2019

    Think you are busy. Take a look at Pfizers commercial team for oncology, which is currently launching four new drugs, three new indications for older drugs, and a biosimilar. And that’s just in the U.S. Its taken some serious internal organizing on Pfizer’s part, but so far managing the ...

    FIERCEPHARMA
    READ MORE

    https://Pharmaceutical.report/news-article.aspx?ID=33163316

    DITCH THE OPIOID 'NEGOTIATING CLASS' PROPOSAL, EXPERTS SAY. STATE ATTORNEYS GENERAL ARE BETTER SUITED TO REACH A DEAL

    Jul 19, 2019

    Cities and counties around the U.S. have sued opioid drugmakers and distributors over their alleged role in a nationwide crisis, and plaintiffs recently proposed a “negotiating class” to help the sides reach a settlement. But that idea isn't helping, two experts say. Instead, it'...

    FIERCEPHARMA
    READ MORE

    https://Pharmaceutical.report/news-article.aspx?ID=33173317

    ASTRAZENECA TO SHELL OUT 12M POUNDS IN SEVERANCE DISPUTE WITH WORKERS AT FORMER ENGLAND PLANT

    Jul 18, 2019

    When AstraZeneca sold its Avlon, England plant to CDMO Avara in 2016, it was touted as a lifeline for the drugmakers 210 on-site employees who faced termination. Three years later, with the plant back on life support, AstraZeneca will have to pony up after those former employees said the British dru...


    READ MORE

    https://Pharmaceutical.report/news-article.aspx?ID=33123312

    BRISTOL-MYERS SQUIBB, BAYER TEAM UP ON OPDIVO-STIVARGA COMBO IN COLORECTAL CANCER

    Jul 18, 2019

    Bristol-Myers Squibb is out to expand the pool of colorectal cancer patients it can treat with Opdivo and its bringing in Bayer to help. The two companies, along with Bristol partner Ono Pharmaceutical, have joined forces in a clinical pact to test the immuno-oncology star alongside Bayers Stivarga ...


    READ MORE

    https://Pharmaceutical.report/news-article.aspx?ID=33133313

    NOVARTIS SICKLE CELL DRUG WINS FDA PRIORITY REVIEW

    Jul 18, 2019

    The US Food and Drug Administration (FDA) has given Novartis investigational sickle cell medicine, crizanlizumab SEG101, Priority Review. The governing body accepted the company's Biologics License Application (BLA) which was submitted for the prevention of vaso-occlusive crises (VOCs) in patien...


    READ MORE

    https://Pharmaceutical.report/news-article.aspx?ID=33143314

    GENDER IMBALANCE EXPECTED IN SENIOR PHARMA ROLES UNTIL 2090

    Jul 18, 2019

    This years definitive Women Count has reported that there has been no progress on gender diversity in senior roles in the FTSE 350, and that only 3.7% of FTSE350 companies have female CEOs  down from 4.6% two years ago. Funded by The Pipeline, the UKs leading gender diversity business, this res...


    READ MORE

    https://Pharmaceutical.report/news-article.aspx?ID=33153315

    GILEAD CEO O DAY CONTINUES TOP-LEVEL REVAMP WITH TWO MORE EXEC EXITS

    Jul 17, 2019

    New Gilead CEO Daniel O Day has already replaced some key leaders at the company, but hes not stopping there with the executive overhaul. Wednesday, the Big Biotech said it would bid farewell to Gregg Alton, its chief patient officer, and Katie Watson, its EVP of human resources. In Watson’s p...


    READ MORE

    https://Pharmaceutical.report/news-article.aspx?ID=33073307

    MERCKS NEW COMBO MED RECARBRIO FIGHTS RESISTANT BACTERIA. CAN IT TACKLE THE SALES CHALLENGE, TOO?

    Jul 17, 2019

    Merck and Co. is one of the few large drugmakers still pursuing antibacterial R and D, and on Wednesday, the company scored approval for a combo drug that tackles serious urinary tract and abdominal infections when other treatments don't work. The FDA signed off on Merck’s Recarbrio, which...


    READ MORE

    https://Pharmaceutical.report/news-article.aspx?ID=33083308

TRENDING NEWS


    ENDO STRIKES 10M DOLLARS OPIOID SETTLEMENT WITH JUST TWO OHIO COUNTIES, AND ALLERGAN MAY NOT BE FAR BEHIND

    Aug 20, 2019

    As the closely-watched opioid litigation in Ohio nears its first trial, Endo has struck a 10 million dollars settlement and Allergan is said to be nearing its own deal. Endo unveiled a 10 million dollars agreement Tuesday that would resolve lawsuits from Ohios Cuyahoga and Summit counties. Meanwhile...


    READ MORE

    https://www.fiercepharma.com/pharma/endo-allergan-near-10m-and-5m-deals-to-settle-two-opioid-lawsuits-wsj3369

    ASTRAZENECAS FARXIGA PADS ITS CASE FOR NEW HEART-HELPING APPROVAL

    Aug 20, 2019

    AstraZeneca is still stinging after its SGLT2 diabetes drug Farxiga was waved off by the FDA in Type 1 disease. But heres something that could ease the pain- New outcomes data showing Farxiga cut cardiovascular risks in heart failure patients with or without diabetes. In a phase 3 trial, Farxiga cut...


    READ MORE

    https://www.fiercepharma.com/pharma/astrazeneca-s-farxiga-shows-reduced-risk-cv-events-as-add-to-standard-care3370

    UNHAPPY PUPILS MORE LIKELY TO BE SMOKERS AND DRINKERS

    Aug 20, 2019

    New figures from NHS Digital have revealed that pupils who have recently smoked, drunk alcohol and taken drugs are more likely to be unhappy. Specifically, 51 Percent of young people aged 11 to 15 who had recently drunk alcohol, smoked cigarettes and taken drugs reported experiencing low levels of h...


    READ MORE

    http://www.pharmatimes.com/news/unhappy_pupils_more_likely_to_be_smokers_and_drinkers_12982463371

    IS PFIZERS ESTABLISHED DRUGS DECLINE IN CHINA THE CANARY IN THE COALMINE?

    Aug 19, 2019

    Big Pharma has been able to count on China to jack up growth for the last several years, but in the second quarter one drugmaker Pfizers Upjohn unit wasnt so fortunate. Is that an ill omen for the rest of multinational pharma? One analyst is posing the question. During the second quarter, Pfizers Up...


    READ MORE

    https://www.fiercepharma.com/pharma-asia/pfizer-established-drugs-drop-china-canary-coalmine3366

    3 DAYS, 5 APPROVALS-CELGENE, ABBVIE, ROCHE MEDS PUSH FDA TALLY TO 23 FOR THE YEAR

    Aug 19, 2019

    Lawmakers may have left the nations capital for summer vacation, but regulators at the FDA are staying busy. The agency churned out five approvals just last week from companies large and small and five more decisions are due by months end. Three of last weeks green lights opened the way for launches...


    READ MORE

    https://www.fiercepharma.com/pharma/5-oks-3-days-celgene-abbvie-and-more-score-drug-approvals-during-busy-week-at-fda3367

    RINVOQ BAGS FDA GREEN LIGHT

    Aug 19, 2019

    AbbVie has announced the US Food and Drug Administration FDA approval of Rinvoq upadacitinib for moderate to severe active rheumatoid arthritis RA. In the SELECT programme, the oral JAK inhibitor met all primary and ranked secondary endpoints across a variety of patients with moderately to severely ...


    READ MORE

    http://www.pharmatimes.com/news/rinvoq_bags_fda_green_light_12980393368

    EBOLA NO LONGER INCURABLE

    Aug 14, 2019

    A new study in the BMJ has identified two new drugs, mAb114 and REGN-EB3, that can dramatically cut mortality from Ebola, and both are being immediately offered to all patients in an effort to control the Democratic Republic of Congos DRC worst ever outbreak. The trial initially compared four potent...


    READ MORE

    http://www.pharmatimes.com/news/ebola_no_longer_incurable_12974453360

    NOVARTIS AVEXIS SHIFTED TOP SCIENTIFIC LEADERSHIP BEFORE ZOLGENSMA DATA SCANDAL ERUPTED

    Aug 14, 2019

    Novartis has said it shuffled staff at its under-the-gun gene therapy unit AveXis. Now we know who and when, at least when it comes to the top scientific leaders in that business. AveXis two top scientists were shunted aside in early May, right around the time Novartis confirmed internally that its ...


    READ MORE

    https://www.fiercepharma.com/pharma/novartis-avexis-shifted-top-scientific-leadership-before-zolgensma-data-scandal-erupted3361

    AZ CALQUENCE GRANTED US BREAKTHROUGH THERAPY DESIGNATION

    Aug 14, 2019

    AstraZeneca has announced that Calquence acalabrutinib has been granted US Breakthrough Therapy Designation BTD for chronic lymphocytic leukaemia. The US Food and Drug Administration FDA granted the designation as a monotherapy treatment for adult patients with the disease, based on positive results...


    READ MORE

    http://www.pharmatimes.com/news/az_calquence_granted_us_breakthrough_therapy_designation_12974443362

    NOVARTIS NAMES BULTO NEW U.S. PHARMA CHIEF AS EXEC RESHUFFLE CONTINUES

    Aug 13, 2019

    Novartis leadership shakeup under CEO Vas Narasimhan has led to a new U.S. pharmaceutical chief. Fabrice Chouraqui, who took on the U.S. job in 2016 from now-Gilead exec Christi Shaw, will step down at the end of August, Novartis said. He will be replaced by Victor Bulto, who currently serves as the...


    READ MORE

    https://www.fiercepharma.com/pharma/novartis-names-bulto-new-u-s-pharma-chief-as-exec-reshuffle-continues3354

    RCGP HIGHLIGHTS DANGERS OF ANTIBIOTICS FOR CHILDREN WHEN NOT ABSOLUTELY NECESSARY

    Aug 13, 2019

    A new study published in the British Journal of General Practice has reported that childhood antibiotic exposure has important clinically relevant implications, including disruption to the microbiome, antibiotic resistance, and clinical workload manifesting as treatment failure. The cohort study, wh...


    READ MORE

    http://www.pharmatimes.com/news/rcgp_highlights_dangers_of_antibiotics_for_children_when_not_absolutely_necessary_12973273355

    GSK EXPERIENCES ANOTHER LEADERSHIP SHAKEUP WITH DEPARTURE OF U.S. PHARMA HEAD

    Aug 13, 2019

    As GlaxoSmithKline continues to evolve its business structure under Chief Executive Officer Emma Walmsley, another leadership change is happening at the top levels. Jack Bailey, head of the companys U.S. pharmaceuticals business is stepping down at the end of the year. Bailey, who has been with GSK ...


    READ MORE

    https://www.biospace.com/article/gsk-taps-merck-kgaa-veteran-to-helm-u-s-pharmaceuticals-business/3356

    HUMANA CALLS MALLINCKRODTS ACTHAR A BILLION-DOLLAR GOLDEN GOOSE IN 700M DOLLARS FRAUD LAWSUIT

    Aug 12, 2019

    Mallinckrodt is getting burned on all sides as federal prosecutors scope out the drugmakers controversial H.P. Acthar Gel marketing and price hikes. Now, one of the largest U.S. insurers is looking to pile on. Humana overpaid for Acthar by 700 million dollars because of Mallinckrodts widespread camp...


    READ MORE

    https://www.fiercepharma.com/pharma/mallinckrodt-defrauded-major-insurer-700m-through-kickbacks-acthar-price-hikes-lawsuit3351

    TREMFYA TOPS COSENTYX IN LATE-STAGE STUDY

    Aug 12, 2019

    Johnson and  Johnsons Janssen has announced results from the Phase III ECLIPSE study, which show superior long-term efficacy of Tremfya guselkumab compared with Cosentyx secukinumab in adults with moderate to severe plaque psoriasis. According to the data, published in The Lancet, a statistical...


    READ MORE

    http://www.pharmatimes.com/news/tremfya_tops_cosentyx_in_late-stage_study_12971743352

    IRKED BY A PHARMA CEOS BROKEN PROMISE? WE ARE MAKING A LIST

    Aug 12, 2019

    Biotech and pharma CEOs are used to having their words recorded. Whether its at an investor conference, an industry confab, a press conference or a quarterly earnings call, CEO statements end up everywhere from webcasts to reporters notebooks. Sometimes, those statements arent just facts. They are p...


    READ MORE

    https://www.fiercepharma.com/pharma/irked-by-a-pharma-ceo-s-broken-promise-we-re-making-a-list3353

    ASTRAZENECA ROCKETS TOWARD TAGRISSO SALES TARGET WITH ANOTHER SURVIVAL WIN

    Aug 09, 2019

    AstraZeneca already has a Tagrisso approval for patients with previously untreated, EGFR-mutated lung cancer. But its shoring up its case with some clutch new data. Friday, the British drugmaker said Tagrisso had beaten out Roches rival drug Tarceva and AstraZenecas own Iressa at helping patients li...

    FIERCE PHARMA
    READ MORE

    https://www.fiercepharma.com/pharma/astrazeneca-rockets-toward-tagrisso-target-another-survival-win3348

SPOTLIGHT

Our partners are our source of guidance; we tailor-make a deal with associates regarding their individual market specifications, because we know there’s more to a contract than merely supply and demand. Every request and query is met with a detailed answer and efficient response time.

RESOURCES

Events